- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03630419
Specialized Food Plan Based on Individual Physiological Comprehensive Body Assessments Accompanied With Cellular Repair Therapy to Decrease Inflammation Cognitively Impaired Patients
October 1, 2018 updated by: Perseverance Research Center, LLC
Determining if a Personalized Mito Food Plan Diet and Cellular Repair Therapy Based on Individual Physiological and Cellular Comprehensive Body Assessments in Patients With Alzheimer's Disease Decreases Inflammation and Oxidative Stress
Diet plays a large role in inflammation, oxidative stress and cognition; however, every person's body type, resting metabolic rate, BMI, and inflammation levels vary.
Through performing physiological and comprehensive cellular testing through bio-impedance, allows this study to create personalized diet plans for each subject's body type.
Cellular repair therapy has also been known to improve cellular health and inflammation.
Through decreasing inflammation and improving oxidative stress, cognition in those with MCI and AD could improve.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Even though AD has been associated with specific hallmarks, multiple etiologies have been suggested to be prominent in the pathogenesis of the disease.
Chronic inflammation, metabolic dysfunction, oxidative stress and mitochondrial damage have all been linked to the incidence and progression of neurodegeneration, negatively impacting overall prognosis of AD.
Currently, only a handful of FDA approved Alzheimer's medications are on the market; yet, these medications are known to only treat symptoms associated with AD, not the underlying causes.
There are currently no medications FDA approved for MCI and predicting who will progress onto AD is unknown.
Unfortunately, in the last decade alone, several clinical trials in MCI and AD, have been terminated prior to study conclusion, due to lack of efficacy and/or poor study design.
Even if an experimental drug is shown to be promising in early stages of testing, it could take up to another 10-15 years before it is FDA approved and made commercially available.
Therefore, the need to find a therapy that could possibly prevent people with MCI from developing AD is imperative.
Through studying different etiologies, providing a specialized diet based on each subject's individual physiological results and improving mitochondria through cell repair therapy, not only can be quickly implemented into the life of a person with cognitive impairment, but could possibly decrease the prevalence and slow disease progression of AD.
Thus, the fundamental research of this study is to determine if such etiologies are measurable in patients with MCI and AD through body composition and cellular health testing that could lead to proper and novel treatments to combat the diseases.
This study was conducted in hopes of determining that chronic inflammation and other risk factors for MCI and AD such as oxidative stress and metabolic dysfunction, can be ameliorated, improve cognitive function, and therefore prevent disease progression through effective, non-drug therapies.
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Arizona
-
Scottsdale, Arizona, United States, 85254
- Perseverance Research Center, LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
53 years to 88 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 55-90 age inclusive
- Male or female
- Clinically definite or probable Alzheimer's Disease (AD) by The Alzheimer's Association and the National Institute on Aging (NIA)
- Must be diagnosed with clinical amnestic Mild Cognitive Impairment
- MMSE > 17
- MOCA>10
- Score a > 4 or greater on the Constructional Praxis exam portion of the Alzheimer's Disease Assessment Scale-Cognitive testing (ADAS-Cog)
- Capable of providing informed consent and complying with trial procedures
- Must be able and willing to keep a diet diary
- Must avoid high-intensity activity 24 hours prior to day of body assessment
- Must avoid all physical exercise for at least three hours prior to day of body assessment
- Must be able to comply to dietary requirements
- Must be on stable dose of all medications and nutritional supplements for at least 3 months prior to screening.
Exclusion Criteria:
- Incapable of providing informed consent
- Incapable of eating solid foods
- Patients diagnosed with Lewy Bodies or Vascular Dementia
- Patients diagnosed with non-amnestic Mild Cognitive Impairment
- MMSE<17
- MOCA<10
- ADAS-COG constructual praxis score <4
- Incapable of obtaining a diet/food diary
- Unstable to comply to study treatments/visits
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Mito-Food Plan and Cellular Repair
Mito-Food Plan with adjunctive Cellular Repair Therapy
|
Specialized anti-inflammatory diet plan based on subject's physiological results
the objective of this type of technology is to support the body's own processes to repair protein structures and maintain the health of the DNA, both of which have been damaged by internal and external factors.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in inflammation as measured through bioimpedance analysis from baseline to week 12
Time Frame: 3 months
|
Mito-Food plan with cellular repair therapy will decrease inflammation in MCI and AD patients
|
3 months
|
Change in Mini Mental State Exam (MMSE) from Baseline to Week 12
Time Frame: 3 months
|
Measuring cognition over the course of treatment as measured by the MMSE
|
3 months
|
Change in Montreal Cognitive Assessment (MoCA) from Baseline to Week 12
Time Frame: 3 months
|
Measuring cognition over the course of treatment as measured by the MoCA
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Quality of Life in Alzheimer's Disease (QOL-AD) from Baseline to Week 12
Time Frame: 3 months
|
Determining if scores on Quality of Life in AD improves over course of therapy
|
3 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in A1C levels from Baseline to Week 12
Time Frame: 3 months
|
Determining if A1c changes over the course of treatment as measured by blood work
|
3 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Study Director: Nicole Hank, PHD, MCR, MHSM, Perseverance Research Center
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 10, 2018
Primary Completion (Actual)
July 28, 2018
Study Completion (Actual)
July 28, 2018
Study Registration Dates
First Submitted
August 8, 2018
First Submitted That Met QC Criteria
August 9, 2018
First Posted (Actual)
August 14, 2018
Study Record Updates
Last Update Posted (Actual)
October 2, 2018
Last Update Submitted That Met QC Criteria
October 1, 2018
Last Verified
October 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Mito-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeRecruitingAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.RecruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Capital Medical UniversityPeking University First Hospital; The First Affiliated Hospital of Anhui Medical... and other collaboratorsRecruitingAlzheimer Disease | Familial Alzheimer Disease (FAD)China
-
University of PennsylvaniaNational Institute on Aging (NIA)CompletedDementia | Alzheimer Disease, At Risk | Alzheimer Disease, Protection AgainstUnited States
-
Kyoto UniversityOsaka University; Mie University; Tokushima University; Tokyo Metropolitan Geriatric... and other collaboratorsCompletedFamilial Alzheimer Disease (FAD) | PSEN1 MutationJapan
-
University of ArizonaNational Institute on Aging (NIA); University of Southern California; Syneos... and other collaboratorsRecruitingNeurodegenerative Diseases | Alzheimer Dementia | Late Onset Alzheimer DiseaseUnited States
-
National Taiwan Normal UniversityCompletedAlzheimer Disease 2 Due to Apoe4 IsoformTaiwan
-
Northwell HealthRecruitingAlzheimer Disease | Alzheimer Disease With Delusions | Alzheimer Disease With PsychosisUnited States
-
University of Kansas Medical CenterNational Institute on Aging (NIA)CompletedHealthy Aging | Alzheimer Disease 2 Due to Apoe4 IsoformUnited States
Clinical Trials on Mito-Food Plan
-
University of Alabama at BirminghamMedifast, Inc.CompletedObesity | Nutrition Disorders | Overweight | Body Weight | Weight LossUnited States
-
Woman'sWoman's Hospital, Louisiana; Dietitians in Integrative and Functional Medicine...Withdrawn
-
Medifast, Inc.Completed
-
Drexel UniversityCompletedObesity | OverweightUnited States
-
Duke UniversityRecruitingCOVID-19 Acute Respiratory Distress SyndromeUnited States
-
University of ArkansasRecruitingPatient Engagement | Chronic Kidney Disease Stage 5 | Chronic Kidney Disease stage4 | Chronic Kidney Disease stage3United States
-
University Hospital, LilleMinistry of Health, FranceUnknown
-
University of California, San FranciscoWashington University School of Medicine; University of Washington; Pacific Pediatric... and other collaboratorsRecruitingMedulloblastoma | Medulloblastoma, Childhood | Medulloblastoma RecurrentUnited States
-
Assistance Publique - Hôpitaux de ParisCompleted
-
Instituto de Investigación Hospital Universitario...Hospital Universitario La Paz; Fundacion para la Investigacion Biomedica del...CompletedSuicidal Ideation | Suicide, Attempted | SuicideSpain